1. Introduction {#sec1}
===============

Human immunodeficiency virus (HIV) is the basis for acquired immune deficiency syndrome (AIDS) pathogenesis and destroys the lymphoid system with prodigious replicates, which reduces a patient\'s ability to survive. Since HIV was identified in the 1980s, this pathogen has taken more than 10 million people\'s lives throughout the world. Researchers have developed considerable information on HIV involving immunology, virology, host genetics, and treatment over the past few decades.

Human genetics research involving the infectious disease HIV has progressed considerably after initiation of the human genome project (HGP), which is sequencing the entire human genome, both physically and functionally \[[@B1]\]. Many host genetic factors that influence AIDS epidemiological heterogeneity have been characterized \[[@B2]--[@B4]\]. From the HIV entry receptor on lymphoid cells to oncogenes in human glioblastomas, AIDS restriction genes (ARGs) are widely involved in biological pathways, and nearly 40 ARGs have been studied in depth through functional analyses \[[@B5]--[@B12]\]. Host genomic analysis is a key approach to studying AIDS epidemiology \[[@B13]\].

Further, genome, transcriptome, proteome, and metabolome biodatasets related to HIV have grown exponentially due to advanced sequencing technology. However, an integrative study on these datasets is limited in terms of understanding the complicated biological network.

Recent studies have revealed that metabolic pathways exert certain effects on the control of AIDS disease progression \[[@B14]\]. For example, the oxygen concentration can modulate T-cell differentiation through controlling metabolic status \[[@B15]\]. Metabolizing ATP to adenosine inhibits HIV-specific effector cells. Further, HIV infection is affected by dNTP hydrolysis. Efficient HIV-1 infection of CD4(+) lymphocytes requires sufficient glucose uptake via the Glut1 glucose transporter \[[@B16]\]. Tryptophan and phenylalanine metabolism also play an important role in HIV because HIV pathophysiology is associated with inflammatory stress due to dysregulated amino acid metabolism \[[@B17]\]. The HIV protein NEF impacts lipid-related metabolism through impairing cholesterol metabolism in both infected and bystander cells \[[@B18], [@B19]\]. This evidence suggests that cross talk between AIDS and the host metabolism is an important research topic that is necessary to resolve the disease mechanism and aid in therapy. Integrating biodatasets with an in-depth analysis of host AIDS restriction genes and metabolic pathways is imperative.

In the transcriptome, gene coexpression is a model for understanding how individual genes are correlated in certain conditions \[[@B20], [@B21]\]. Based on advances in this field, researchers hypothesize that the coexpression of genes in certain pathways indicates an integrative correlation between the two molecular pathways. Full genes in metabolic pathway are available for the human genome. Identifying correlations between a group of metabolic pathway genes and ARGs is a more comprehensive means for understanding integrative biodatasets. However, traditional methods using a Pearson or partial correlation are only suitable for a single gene. A canonical correlation analysis (CCA) is an efficient and powerful approach for measuring coexpression between two sets of genes. A Childhood Asthma Management Program (CAMP) study using a CCA successfully detected genetic regulatory variants \[[@B22]\]. Using the CCA, the glioblastoma transcriptomes of 45 patients were thoroughly analyzed to identify the glioma pathway genes \[[@B23]\].

In this paper, we used a CCA to analyze coexpression between ARGs and metabolic pathways from KEGG. We discuss the most important metabolic pathways coexpressed with the ARGs, which may imply strategies for AIDS diagnosis and therapy.

2. Methods {#sec2}
==========

2.1. Datasets {#sec2.1}
-------------

Human genome expression datasets were downloaded from the website COPRESDB (<http://coxpresdb.jp/>), which contains approximately 4000 experiments and expression data on 20,000 human genes. Metabolic pathway genes were downloaded from KEGG (<http://www.kegg.jp/>); this dataset includes 129 typical metabolic pathways with predicted genes. The ARGs were collected from published literature. Two expression datasets were generated to include metabolic pathway gene and ARG expression data, respectively (Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"}).

2.2. Canonical Correlation Analysis {#sec2.2}
-----------------------------------

To analyze the correlations between ARG and metabolic pathway gene expression, we used a CCA, which integrates multiple correlations into a few significant correlations. This statistical method calculates the correlation between two sets of variables and generates statistically independent pairs of new variables, which are referred to as canonical variables. The linear combination of the variables creates a component of the canonical variable pair in each group of the original variables.

In this study, these variables were defined at each flag as follows: ARG expression described by *M* genes in the vector *c* = (*c* ~1~, *c* ~2~,..., *c* ~*M*~) and metabolic pathway gene expression described by *N* genes in the vector *k* = (*k* ~1~, *k* ~2~,..., *k* ~*M*~). The respective sets of canonical variables *s* = (*s* ~1~, *s* ~2~,..., *s* ~*M*~) and *p* = (*p* ~1~, *p* ~2~,..., *p* ~*M*~) are results from the linear combination of ARG and metabolic pathway gene expression. The ARG expression canonical variables are included in the vector *s*, which is the result of the linear combination comprising the *c* vector (original ARGs expression) and the canonical coefficients vector as *s* = *A*′*c*. The vector contains the canonical variables for metabolic pathway gene expression, which result from the linear combination of the vector (original metabolic pathway genes expression) and canonical coefficient vector. The ARG and metabolic pathway gene variance-covariance matrices can be used to estimate the canonical correlation coefficients.

The magnitude of the correlation between each pair of canonical variables is described by the vector *k* ~*i*~ eigenvalues. The canonical coefficients exist in the eigenvectors and can be used to estimate the canonical variables. The variance-covariance matrices contain the variances and covariances within the groups for the ARGs and metabolic pathway genes, respectively. The covariances between variables were calculated from the variance-covariance matrices.

2.3. The Study Design and Software Tools {#sec2.3}
----------------------------------------

The canonical correlation analysis was performed using the R platform (<http://www.r-project.org/>). After the canonical variables were generated from the expression datasets composed of ARGs and metabolic pathway genes, we set the absolute value 0.15 as the threshold for selecting ARGs correlated with canonical variables. To select metabolic pathway genes correlated with canonical variables, we sorted the genes using the absolute value, and the top 50 were selected for further enrichment analyses. Functional annotations were generated and enrichment analyses were performed for the metabolic pathway genes using the web-based DAVID tool (<http://david.abcc.ncifcrf.gov/>). For the pathway enrichment analyses, the "KEGG_PATHWAY" was selected. The pathways with a *P* value \< 0.01 were considered significant.

3. Results {#sec3}
==========

3.1. The ARGs and Metabolic Pathway Genes {#sec3.1}
-----------------------------------------

### 3.1.1. The General CCA Results {#sec3.1.1}

Eight significant (*P* \< 0.01, Wilk\'s Lambda, *r* \> 0.95) canonical correlations were discerned between the ARG and metabolic pathway gene transcriptomes using the CCA. 60% of the total ARG expression variance was explained by the ARGs canonical variables. Significant metabolic pathway canonical variables explained 38% of the metabolic gene transcriptome variation. Thus, ARG-metabolic pathway associations were involved in a substantial proportion of the total variance. The first pair of canonical variables had a correlation of 0.99, while the second pair of canonical variables had a correlation of 0.98.

3.2. Relationships between the Canonical Variables and Original Genes {#sec3.2}
---------------------------------------------------------------------

### 3.2.1. Pair 1 (*C*1,*P*1) {#sec3.2.1}

As shown in [Table 3](#tab3){ref-type="table"}, the canonical variable*C*1 explains 2.4% of the variability in the original ARGs expression variables. We observed positive correlations (absolute value \> 0.15) with all ARGs, including PPIA (0.42), ZNRD1 (0.37), MYH9 (0.36), TSG101 (0.31), IDH1 (0.28), TRIM5a (0.17), and CUL5 (0.15), but not GML (−0.17) and NCOR2 (−0.31). The greatest positive correlation was observed between *C*1 and PPIA. In contrast, the greatest negative correlation was observed between *C*1 and NCOR2. Among seven ARGs with positive correlations, the four ARGs, PPIA, TSG101, TRIM5a, and CUL5, are postentry cellular viral cofactors.

As shown in [Table 4](#tab4){ref-type="table"}, the canonical variable *P*1 accounts for the variability in the original metabolic pathway gene expression data. The metabolic pathway genes that correlated with variable *P*1 were enriched for purine metabolism; these genes include phosphodiesterase 4C (5143), polymerase (RNA) III (DNA directed) polypeptide K (51728), and primase (5558).

### 3.2.2. Pair 2 (*C*2,*P*2) {#sec3.2.2}

As shown in [Table 3](#tab3){ref-type="table"}, the canonical variable *C*2 explains 5.3% of the variability in the original ARG expression variables. This variable highly correlated with the ARGs PPIA (0.92), CUL5 (0.51), TSG101 (0.48), IDH1 (0.17), and PECI (0.15), but not GML (−0.16), APOBEC3G (−0.17), MYH9 (−0.17), IL4 (−0.18), TLR9 (−0.18), CXCR1 (−0.25), HLA-C (−0.26), NCOR2 (−0.28), DC-SIGN (−0.29), and TLR8 (−0.36). The greatest positive correlation was observed between *C*2 and PPIA. However, the greatest negative correlation was observed between *C*2 and DC-SIGN. Among the ARGs with large correlations, PPIA, TSG101, CUL5, and APOBEC3G are postentry cellular viral cofactors. Among the ARGs with negative correlations, CXCR1 and IL4 are related to cytokines. DC-SIGN is involved in chemokines, which play important role in HIV entry through chemokine receptors.

As shown in [Table 4](#tab4){ref-type="table"}, the canonical variable *P*2 accounts for the variability in the original metabolic pathway gene expression data. The metabolic pathway genes that highly correlate with the variable *P*2 are not enriched in a certain pathway.

### 3.2.3. Pair 3 (*C*3,*P*3) {#sec3.2.3}

As shown in [Table 3](#tab3){ref-type="table"}, the canonical variable *C*3 explains 12.7% of the variability on the original ARG expression variables. This variable positively correlated (absolute value \> 0.15) with PPIA (1.88), NCOR2 (0.37), ZNRD1 (0.28), MYH9 (0.21), CXCR1 (0.20), and Slurp1 (0.19); in contrast, it negatively correlated with TRIM5a (−0.15), SDF1 (−0.17), IDH1 (−0.22), PECI (−0.24), TSG101 (−0.25), and CUL5 (−0.87). The greatest positive correlation was observed between *C*1 and PPIA. However, the greatest negative correlation was observed between *C*3 and CUL5. Among the ARGs that highly correlated with *C*3, PPIA, TSG101, TRIM5a, and CUL5 are postentry cellular viral cofactors. However, only PPIA positively correlated with *C*3.

As shown in [Table 4](#tab4){ref-type="table"}, the canonical variable *P*3 accounts for the variability in the original metabolic pathway gene expression data. The metabolic pathway genes that highly correlated with the variable *P*3 are enriched in glycolysis and pyrimidine metabolism. The glycolysis genes include phosphoglycerate mutase 1 (5223), glyceraldehyde-3-phosphate dehydrogenase (2597), and glucose-6-phosphatase (57818). The pyrimidine metabolism genes include polymerase (DNA directed), delta 2 (5425), cytidine monophosphate (UMP-CMP) kinase 1 (51727), and uridine monophosphate synthetase (7372).

### 3.2.4. Pair 4 (*C*4,*P*4) {#sec3.2.4}

As shown in [Table 3](#tab3){ref-type="table"}, the canonical variable *C*4 explains 3.3% of the variability in the original ARG expression variables. This variable highly correlated (absolute value \> 0.15) with PPIA (0.58), TLR8 (0.30), TLR4 (0.24), and PROX1 (0.16), but not DEFB1 (−0.15), IDH1 (−0.17), SDF1 (−0.18), CUL5 (−0.23), LY6D (−0.24), NCOR2 (−0.27), and Slurp1 (−0.61). The greatest positive correlation was observed between *C*4 and PPIA. However, the greatest negative correlation was observed between *C*4 and Slurp1. Among the ARGs that highly correlated with *C*3, only PPIA and CUL5 are postentry cellular viral cofactors.

As shown in [Table 4](#tab4){ref-type="table"}, the canonical variable *P*4 accounts for the variability in the original metabolic pathway gene expression data. The metabolic pathway genes that highly correlated with the variable *P*4 are enriched in purine metabolism. These genes include deoxyguanosine kinase (1716), polymerase (RNA) III (DNA directed) polypeptide K (51728), polymerase (RNA) III (DNA directed) polypeptide B (55703), pyruvate kinase (5313), adenylate cyclase 10 (55811), phosphodiesterase 6D (5147), polymerase (DNA directed), delta 2 (5425), polymerase (RNA) II (DNA directed) polypeptide C (5432), and phosphodiesterase 5A (8654).

### 3.2.5. Pair 5 (*C*5,*P*5) {#sec3.2.5}

As shown in [Table 3](#tab3){ref-type="table"}, the canonical variable *C*5 explains 8.3% of the variability in the original ARG expression variables. This variable highly correlated (absolute value \> 0.15) with IDH1 (0.60), TLR8 (0.33), ZNRD1 (0.32), TRIM5a (0.26), IRF1 (0.23), PROX1 (0.23), Slurp1 (0.21), HLA-C (0.21), GML (0.21), CUL5 (0.19), CXCR1 (0.17), TSG101 (0.17), APOBEC3B (0.15), TLR4 (−0.15), DC-SIGN (−0.17), SDF1 (−0.26), HLA-B (−0.41), MYH9 (−0.49), PPIA (−0.54), and NCOR2 (−1.10). The greatest positive correlations were observed between *C*5 and IDH1. However, the greatest negative correlations were observed between *C*5 and NCOR2. Among the ARGs that highly correlated with *C*5, PPIA, TSG101, APOBEC3B, TRIM5a, and CUL5 are postentry cellular viral cofactors. HLA-C and HLA-B are members of the HLA system. DC-SIGN and SDF1 are related to chemokines. CXCR1 is related to the cytokines pathway.

As shown in [Table 4](#tab4){ref-type="table"}, the canonical variable *P*5 accounts for the variability in the original metabolic pathway gene expression data. The metabolic pathway genes that highly correlated with the variable *P*5 are enriched in inositol phosphate metabolism; these genes include synaptojanin 2 (8871), phospholipase C beta 2 (5330), and inositol-trisphosphate 3-kinase B (3707).

### 3.2.6. Pair 6 (*C*6,*P*6) {#sec3.2.6}

As shown in [Table 3](#tab3){ref-type="table"}, the canonical variable *C*6 explains 10.8% of the variability in the original ARG expression variables. This variable highly correlated (absolute value \> 0.15) with PPIA (1.11), TLR8 (0.70), TSG101 (0.49), CUL5 (0.40), Slurp1 (0.32), TLR4 (0.26), HLA-B (0.25), CXCR6 (0.18), TLR9 (−0.17), IDH1 (−0.20), HLA-A (−0.22), IRF1 (−0.24), NCOR2 (−0.24), TRIM5a (−0.30), HLA-C (−0.33), CXCR1 (−0.40), MYH9 (−0.50), and ZNRD1 (−0.91). The greatest positive correlation was observed between *C*6 and PPIA. However, the greatest negative correlation was observed between *C*6 and ZNRD1. Among the ARGs that highly correlated with *C*6, PPIA, TSG101, TRIM5a, and CUL5 are postentry cellular viral cofactors. HLA-A, HLA-C, and HLA-B are members of the HLA system. CXCR6 is related to chemokine receptors. IRF1 and CXCR1 are related to cytokines.

As shown in [Table 4](#tab4){ref-type="table"}, the canonical variable *P*6 accounts for the variability in the original metabolic pathway gene expression data. The metabolic pathway genes that highly correlated with variable *P*6 are enriched in pyrimidine metabolism and terpenoid backbone biosynthesis. These genes include polymerase (RNA) II (DNA directed) polypeptide F (5435), cytidine monophosphate (UMP-CMP) kinase 1 (51727), polymerase (RNA) I polypeptide B (84172), farnesyl diphosphate synthase (2224), and acetyl-CoA acetyltransferase 1 (38).

### 3.2.7. Pair 7 (*C*7,*P*7) {#sec3.2.7}

As shown in [Table 3](#tab3){ref-type="table"}, the canonical variable *C*7 explains 9% of the variability in the original ARG expression variables. This variable highly correlated (absolute value \> 0.15) with IDH1 (1.12), PROX1 (0.55), CCL11 (0.25), DC-SIGN (0.22), TRIM5a (0.22), KIR (0.17), IL4 (−0.15), TLR8 (−0.15), HLA-C (−0.22), TLR9 (−0.24), PECI (−0.35), NCOR2 (−0.38), APOBEC3G (−0.44), TSG101 (−0.54), and CUL5 (−0.80). The greatest positive correlation was observed between *C*7 and IDH1. However, the greatest negative correlation was observed between *C*7 and CUL5. Among the ARGs that highly correlated with *C*7, TSG101, APOBEC3G, TRIM5a, and CUL5 are postentry cellular viral cofactors. KIR and HLA-C are in the HLA system. DC-SIGN and CCL11 are related to chemokine receptors. IL4 is related to cytokines.

As shown in [Table 4](#tab4){ref-type="table"}, the canonical variable *P*7 accounts for the variability in the original metabolic pathway gene expression data. The metabolic pathway genes that highly correlated with variable *P*7 are enriched in pyrimidine metabolism and methane metabolism. These genes include uridine-cytidine kinase 1-like 1 (54963), polymerase (RNA) II (DNA directed) polypeptide F (5435), polymerase (RNA) II (DNA directed) polypeptide A (5430), alcohol dehydrogenase 5 (class III) (128), and methylenetetrahydrofolate reductase (4524).

### 3.2.8. Pair 8 (*C*8,*P*8) {#sec3.2.8}

As shown in [Table 3](#tab3){ref-type="table"}, the canonical variable *C*8 explains 12% of the variability in the original ARG expression variables. This variable highly correlated (absolute value \> 0.15) with PPIA (1.12), IDH1 (0.63), TRIM5a (0.53), NCOR2 (0.52), APOBEC3G (0.39), TLR9 (0.36), DC-SIGN (0.33), IL4 (0.30), PECI (0.25), SDF1 (0.22), TLR8 (0.17), MYH9 (−0.19), HLA-C (−0.21), IRF1 (−0.24), HLA-B (−0.31), PROX1 (−0.66), and TSG101 (−1.03). The greatest positive correlation was observed between *C*8 and PPIA. However, the greatest negative correlation was observed between *C*8 and TSG101. Among the ARGs that highly correlated with *C*8, TSG101, APOBEC3G, TRIM5a, and PPIA are postentry cellular viral cofactors. KIR and HLA-C are in the HLA system. DC-SIGN and SDF1 are related to chemokine receptors. IL4 and IRF1 are related to cytokines. HLA-C and HLA-B are in the HLA system.

As shown in [Table 4](#tab4){ref-type="table"}, the canonical variable *P*8 accounts for the variability in the original metabolic pathway gene expression data. The metabolic pathway genes that highly correlated with variable *P*8 are not enriched in a metabolic pathway.

4. Discussion {#sec4}
=============

Researchers have used numerous approaches to identify host genes related to AIDS \[[@B5]--[@B13]\]. Most studies use genomic information but not integration of the genome and transcriptome. However, most SNPs at ARGs impact AIDS through changing host gene transcription \[[@B7]--[@B10]\]. This study features novel experiments that focus on ARG cooperation at the transcription level and extends the correlation between ARGs and metabolic pathway genes to discover novel host genes related to AIDS.

For each variable in the canonical correlation analysis, HIV-1 postentry cellular viral cofactors highly cooperated at the transcription level. PPIA, TSG101, TRIM5a, APOBEC3G, and CUL5 frequently appeared together to correlate with the canonical variables. PPIA functions in cyclosporin A-mediated immunosuppression by encoding a member of the peptidyl-prolyl cis-trans isomerase (PPIase) family \[[@B24]\]. Formation of HIV virions requires an interaction between PPIA and HIV viral proteins. TSG101 negatively regulates cell growth and differentiation by producing a protein that interacts with stathmin \[[@B25]\]. TRIM5a is an E3 ubiquitin-ligase, and its ubiquitination function is involved in retroviral restriction \[[@B26]\]. These genes encode HIV-1 postentry cellular viral cofactors involved in different biological processes. Thus, the high correlation between these genes and canonical variables demonstrates that these genes are coordinated at the transcriptional level. These data suggest that a potential transcriptional regulator for these genes may be a key host factor related to AIDS.

The high-frequency ARGs that correlated with canonical variables include PPIA, TSG101, CUL5, NCOR2, IDH1, and MYH9. PPIA, TSG101, and CUL5 are discussed above. NCOR2 with histone deacetylases is a nuclear receptor corepressor \[[@B27]\]. IDH1 encodes isocitrate dehydrogenases involved in cytoplasmic NADPH production and pyruvate metabolism \[[@B28]\]. MYH9 aids in maintaining cell shape, cell motility, and cytokinesis as a conventional nonmuscle myosin \[[@B29]\]. These ARGs are not enriched in a certain biological process. However, many host genetic factors have not been studied.

The low-frequency ARGs that correlated with canonical variables include DEFB1 with *C*4, KIR with *C*7, HLA-A with *C*5, CCL11 with *C*7, LY6D with *C*4, APOBEC3B with *C*5, and CXCR6 with *C*6. DEFB1 is a defensin and is implicated in cystic fibrosis pathogenesis \[[@B30]\]. HLA-A is a major histocompatibility complex class I heavy chain paralogue; these paralogues are expressed in nearly all cells \[[@B31]\]. CCL11 is chemokine (C-C motif) ligand 11 and is implicated in immunoregulatory and inflammatory processes \[[@B32]\]. CXCR6 is chemokine (C-X-C motif) receptor \[[@B33]\]. LY6D is a member of the lymphocyte antigen 6 complex \[[@B34]\]. APOBEC3B is a member of the cytidine deaminase gene family. Recent studies have revealed that these ARGs may be RNA-editing enzymes that control the cell cycle \[[@B35]\]. Further, these genes only correlated with one canonical variable, which suggests that the specificity of the correlation may determine the canonical variable correlated with a certain metabolic pathway.

The most significant metabolic pathway in our analysis is purine metabolism, which featured correlations with two canonical variables and the lowest *P* values. Recent studies analyzed purine codon patterns in variable and constant regions of HIV-1 and showed that HIV-1 RNA exhibits extreme enrichment in the purine A compared with most organisms \[[@B36]\]. These data suggest that a potential therapeutic agent against HIV-1 may involve novel purine derivatives \[[@B37]\]. Studies have elucidated twenty-four purine derivatives that act as HIV-1 Tat TAR interaction inhibitors \[[@B38]\]. More recently, research revealed that host cells with a modified purine biosynthesis pathway exhibit increased activity by tenofovir against sensitive and drug resistant HIV-1 \[[@B39]\]. In this study, we show a high correlation between ARG and purine metabolism gene expression. These data imply that purine metabolism genes are significant candidates for studying the host genomic or transcriptome influence on AIDS.

5. Conclusions {#sec5}
==============

In this study, we used a CCA to analyze the correlations between ARG and metabolic pathway gene expression. The results show that HIV-1 postentry cellular viral cofactors are highly coexpressed, which suggests that regulating this group of host genes may be a key factor in studies to understand the AIDS-host interaction mechanism. Furthermore, we show that purine metabolism pathway genes coordinate with ARGs; this novel discovery supports future studies on AIDS therapy using purine derivatives. Both coexpressed ARGs and metabolic pathway genes also provide a new marker for AIDS diagnosis.
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###### 

HIV host genetic factor genes.

  Gene symbol   Gene ID   Effect
  ------------- --------- -------------------------
  APOBEC3B      9582      Increase infection
  APOBEC3G      60489     Accelerates AIDS
  CCL11         6356       
  CCL17         6361       
  CCL18         6362       
  CCL2          6347       
  CCL4          6351       
  CCL5          6352       
  CUL5          8065      Accelerates CD4 loss
  CXCR1         3577       
  CXCR6         10663     Accelerates AIDS
  DC-SIGN       30835     Decreases infection
  DEFB1         1672       
  GML           2765       
  HCP5          10866     HIV set point
  HLA-A         3105      Delays AIDS
  HLA-B         3106      Delays AIDS
  HLA-C         3107      Delays AIDS
  IDH1          3417      Prevents infection
  IFENG         3458      Accelerates AIDS
  IL10          3586      Accelerates AIDS
  IL4           3565       
  IRF1          3659       
  KIR           2669      Delays AIDS
  LY6D          8581       
  MYH9          4627      End stage renal disease
  NCOR2         9612      Increase infection
  PECI/ECI2     10455     Accelerates AIDS
  PPIA/CypA     5478      Accelerates AIDS
  PROX1         5629      Delays AIDS progression
  SDF1/CXCL12   6387      Delays AIDS
  Slurp1        57152      
  Slurp2/Ly6    6004       
  TLR4          7099       
  TLR8          51311      
  TLR9          54106      
  TRIM5a        85363     Increase infection
  TSG101        7251      Accelerates AIDS
  ZNRD1         30834      

###### 

Human metabolism pathway for KEGG.

  Pathway name                                                           KEGG ID   Class of metabolism pathway                   Gene number
  ---------------------------------------------------------------------- --------- --------------------------------------------- -------------
  Glycolysis/gluconeogenesis                                             10        Carbohydrate metabolism                       67
  Citrate cycle (TCA cycle)                                              20        Carbohydrate metabolism                       31
  Pentose phosphate pathway                                              30        Carbohydrate metabolism                       29
  Pentose and glucuronate interconversions                               40        Carbohydrate metabolism                       34
  Fructose and mannose metabolism                                        51        Carbohydrate metabolism                       36
  Galactose metabolism                                                   52        Carbohydrate metabolism                       30
  Ascorbate and aldarate metabolism                                      53        Carbohydrate metabolism                       27
  Starch and sucrose metabolism                                          500       Carbohydrate metabolism                       56
  Amino sugar and nucleotide sugar                                       520       Carbohydrate metabolism                       49
  Pyruvate metabolism                                                    620       Carbohydrate metabolism                       42
  Glyoxylate and dicarboxylate metabolism                                630       Carbohydrate metabolism                       24
  Propanoate metabolism                                                  640       Carbohydrate metabolism                       32
  Butanoate metabolism                                                   650       Carbohydrate metabolism                       29
  Inositol phosphate metabolism                                          562       Carbohydrate metabolism                       61
  Oxidative phosphorylation                                              190       Energy metabolism                             133
  Nitrogen metabolism                                                    910       Energy metabolism                             27
  Sulfur metabolism                                                      920       Energy metabolism                             18
  Fatty acid biosynthesis                                                61        Lipid metabolism                              6
  Fatty acid elongation                                                  62        Lipid metabolism                              23
  Fatty acid metabolism                                                  71        Lipid metabolism                              44
  Ketone bodies                                                          72        Lipid metabolism                              9
  Steroid biosynthesis                                                   100       Lipid metabolism                              18
  Primary bile acid biosynthesis                                         120       Lipid metabolism                              17
  Steroid hormone biosynthesis                                           140       Lipid metabolism                              56
  Glycerolipid metabolism                                                561       Lipid metabolism                              55
  Glycerophospholipid metabolism                                         564       Lipid metabolism                              91
  Ether lipid metabolism                                                 565       Lipid metabolism                              42
  Sphingolipid metabolism                                                600       Lipid metabolism                              47
  Arachidonic acid metabolism                                            590       Lipid metabolism                              68
  Linoleic acid metabolism                                               591       Lipid metabolism                              33
  Alpha-linolenic acid metabolism                                        592       Lipid metabolism                              25
  Biosynthesis of unsaturated fatty acids                                1040      Lipid metabolism                              21
  Purine metabolism                                                      230       Nucleotide metabolism                         173
  Pyrimidine metabolism                                                  240       Nucleotide metabolism                         107
  Alanine, aspartate, and glutamate metabolism                           250       Amino acid metabolism                         32
  Glycine, serine, and threonine metabolism                              260       Amino acid metabolism                         37
  Cysteine and methionine metabolism                                     270       Amino acid metabolism                         34
  Valine, leucine, and isoleucine degradation                            280       Amino acid metabolism                         44
  Valine, leucine, and isoleucine biosynthesis                           290       Amino acid metabolism                         2
  Lysine biosynthesis                                                    300       Amino acid metabolism                         2
  Lysine degradation                                                     310       Amino acid metabolism                         49
  Arginine and proline metabolism                                        330       Amino acid metabolism                         57
  Histidine metabolism                                                   340       Amino acid metabolism                         28
  Tyrosine metabolism                                                    350       Amino acid metabolism                         39
  Phenylalanine metabolism                                               360       Amino acid metabolism                         18
  Tryptophan metabolism                                                  380       Amino acid metabolism                         40
  Phenylalanine, tyrosine, and tryptophan biosynthesis                   400       Amino acid metabolism                         5
  Beta-alanine metabolism                                                410       Metabolism of other amino acids               29
  Taurine and hypotaurine metabolism                                     430       Metabolism of other amino acids               10
  Selenocompound metabolism                                              450       Metabolism of other amino acids               17
  Cyanoamino acid metabolism                                             460       Metabolism of other amino acids               7
  D-Glutamine and D-glutamate metabolism                                 471       Metabolism of other amino acids               4
  D-Arginine and D-ornithine metabolism                                  472       Metabolism of other amino acids               1
  Glutathione metabolism                                                 480       Metabolism of other amino acids               51
  N-Glycan biosynthesis                                                  510       Glycan biosynthesis and metabolism            49
  Mucin type O-glycan biosynthesis                                       512       Glycan biosynthesis and metabolism            31
  Other types of O-glycan biosynthesis                                   514       Glycan biosynthesis and metabolism            30
  Glycosaminoglycan biosynthesis, chondroitin sulfate/dermatan sulfate   532       Glycan biosynthesis and metabolism            20
  Glycosaminoglycan biosynthesis, heparan sulfate/heparin                534       Glycan biosynthesis and metabolism            24
  Glycosaminoglycan biosynthesis, keratan sulfate                        533       Glycan biosynthesis and metabolism            15
  Glycosaminoglycan degradation                                          531       Glycan biosynthesis and metabolism            19
  Glycosylphosphatidylinositol- (GPI-) anchor biosynthesis               563       Glycan biosynthesis and metabolism            25
  Glycosphingolipid biosynthesis, lacto- and neolactoseries              601       Glycan biosynthesis and metabolism            26
  Glycosphingolipid biosynthesis, globoseries                            603       Glycan biosynthesis and metabolism            14
  Glycosphingolipid biosynthesis, ganglioseries                          604       Glycan biosynthesis and metabolism            15
  Other glycan degradation                                               511       Glycan biosynthesis and metabolism            18
  Thiamine metabolism                                                    730       Metabolism of cofactors and vitamins          4
  Riboflavin metabolism                                                  740       Metabolism of cofactors and vitamins          13
  Vitamin B6 metabolism                                                  750       Metabolism of cofactors and vitamins          6
  Nicotinate and nicotinamide metabolism                                 760       Metabolism of cofactors and vitamins          28
  Pantothenate and CoA biosynthesis                                      770       Metabolism of cofactors and vitamins          17
  Biotin metabolism                                                      780       Metabolism of cofactors and vitamins          3
  Lipoic acid metabolism                                                 785       Metabolism of cofactors and vitamins          3
  Folate biosynthesis                                                    790       Metabolism of cofactors and vitamins          14
  One carbon pool by folate                                              670       Metabolism of cofactors and vitamins          20
  Retinol metabolism                                                     830       Metabolism of cofactors and vitamins          68
  Porphyrin and chlorophyll metabolism                                   860       Metabolism of cofactors and vitamins          43
  Ubiquinone and other terpenoid-quinone biosynthesis                    130       Metabolism of cofactors and vitamins          10
  Terpenoid backbone biosynthesis                                        900       Metabolism of terpenoids and polyketides      21
  Caffeine metabolism                                                    232       Biosynthesis of other secondary metabolites   7
  Butirosin and neomycin biosynthesis                                    524       Biosynthesis of other secondary metabolites   5
  Metabolism of xenobiotics by cytochrome P450                           980       Xenobiotics biodegradation and metabolism     80
  Drug metabolism, cytochrome P450                                       982       Xenobiotics biodegradation and metabolism     74
  Drug metabolism, other enzymes                                         983       Xenobiotics biodegradation and metabolism     51

###### 

Cross-correlation of Hf genes with canonical variate.

  Gene symbol   *C*1        *C*2        *C*3        *C*4        *C*5        *C*6        *C*7        *C*8
  ------------- ----------- ----------- ----------- ----------- ----------- ----------- ----------- -----------
  DEFB1         0.01        0.01        0.02        −**0.15**   0.06        −0.02       −0.14       −0.04
  KIR           0.08        −0.02       −0.05       −0.01       −0.14       0.08        **0.17**    −0.12
  GML           −**0.17**   −**0.16**   0.12        −0.06       **0.21**    −0.06       0.03        0.07
  HLA-A         0.10        −0.14       −0.01       0.00        −0.03       −**0.22**   −0.13       −0.09
  HLA-B         0.10        0.09        0.12        0.12        −**0.41**   **0.25**    0.07        −**0.31**
  HLA-C         0.07        −**0.26**   −0.04       −0.08       **0.21**    −**0.33**   −**0.22**   −**0.21**
  IDH1          **0.28**    **0.17**    −**0.22**   −**0.17**   **0.60**    −**0.20**   **1.12**    **0.63**
  IFENG         0.00        0.03        0.08        0.07        0.05        −0.09       −0.12       −0.07
  IL4           −0.12       −**0.18**   0.08        0.05        0.01        −0.10       −**0.15**   **0.30**
  CXCR1         −0.07       −**0.25**   **0.20**    0.00        **0.17**    −**0.40**   −0.14       0.08
  IL10          −0.02       −0.05       0.02        0.13        0.05        −0.04       −0.05       −0.01
  IRF1          0.07        −0.09       0.08        0.10        **0.23**    −**0.24**   −0.14       −**0.24**
  MYH9          **0.36**    −**0.17**   **0.21**    −0.14       −**0.49**   −**0.50**   0.14        −**0.19**
  PPIA/CypA     **0.42**    **0.92**    **1.88**    **0.58**    −**0.54**   **1.11**    0.00        **1.12**
  PROX1         −0.14       0.07        0.03        **0.16**    **0.23**    0.02        **0.55**    −**0.66**
  Slurp2/Ly6    −0.04       −0.03       0.00        0.10        −0.13       0.12        0.09        0.02
  CCL2          0.02        −0.03       −0.04       0.00        −0.05       0.12        0.08        0.00
  CCL4          0.02        −0.06       0.02        0.09        0.02        0.05        0.04        −0.06
  CCL5          0.03        −0.06       0.01        0.03        0.00        0.02        −0.14       0.05
  CCL11         0.02        −0.05       0.01        0.02        0.09        −0.01       **0.25**    −0.05
  CCL17         0.00        −0.06       0.05        0.07        0.06        −0.02       −0.19       −0.06
  CCL18         0.03        −0.04       0.00        0.06        0.05        0.14        0.09        0.05
  SDF1/CXCL12   0.09        −0.10       −**0.17**   −**0.18**   −**0.26**   0.14        0.09        **0.22**
  TLR4          0.06        −0.05       −0.02       **0.24**    −**0.15**   **0.26**    0.00        0.02
  TSG101        **0.31**    **0.48**    −**0.25**   −0.05       **0.17**    **0.49**    −**0.54**   −**1.03**
  CUL5          **0.15**    **0.51**    −**0.87**   −**0.23**   **0.19**    **0.40**    −**0.80**   −0.04
  LY6D          0.01        −0.05       0.10        −**0.24**   0.10        0.13        0.01        −0.08
  APOBEC3B      0.04        0.03        0.04        0.03        **0.15**    −0.12       0.02        0.14
  NCOR2         −**0.31**   −**0.28**   **0.37**    −**0.27**   −**1.10**   −**0.24**   −**0.38**   **0.52**
  PECI/ECI2     0.09        **0.15**    −**0.24**   0.01        −0.10       0.06        −**0.35**   **0.25**
  CXCR6         −0.06       −0.10       0.02        −0.06       0.03        **0.18**    −0.07       0.09
  HCP5          −0.04       0.02        −0.01       −0.01       0.32        0.01        0.02        −0.01
  ZNRD1         **0.37**    0.14        **0.28**    −0.03       **0.32**    −**0.91**   −0.04       0.10
  DC-SIGN       −0.04       −**0.29**   0.13        0.00        −**0.17**   0.03        **0.22**    **0.33**
  TLR8          0.13        −**0.36**   −0.03       **0.30**    **0.33**    **0.70**    **−0.15**   **0.17**
  TLR9          −0.03       −**0.18**   0.11        −0.06       −0.02       −**0.17**   **−0.24**   **0.36**
  Slurp1        −0.03       −0.10       **0.19**    −**0.61**   **0.21**    **0.32**    0.04        −0.06
  APOBEC3G      0.06        −**0.17**   −0.14       0.11        0.19        0.07        −**0.44**   **0.39**
  TRIM5a        **0.17**    −0.13       −**0.15**   0.00        **0.26**    −**0.30**   **0.22**    **0.53**

###### 

Cross-correlation of genes enriched in metabolic pathways with canonical variate.

  Component   Term                              Count   Pop hits   *P* value      Genes
  ----------- --------------------------------- ------- ---------- -------------- -------------------------------
  *P*1+       Purine metabolism                 3       153        4.87*E* − 02   5143, 51728, 5558
  *P*3+       Glycolysis/gluconeogenesis        3       60         1.14*E* − 02   5223, 2597, 57818
  *P*3+       Pyrimidine metabolism             3       95         2.72*E* − 02   5425, 51727, 7372
  *P*4−       Purine metabolism                 4       153        7.62*E* − 03   1716, 51728, 55703, 5313
  *P*4+       Purine metabolism                 5       153        6.23*E* − 04   55811, 5147, 5425, 5432, 8654
  *P*5−       Inositol phosphate metabolism     3       54         6.82*E* − 03   8871, 5330, 3707
  *P*6−       Pyrimidine metabolism             3       95         2.72*E* − 02   5435, 51727, 84172
  *P*6+       Pyruvate metabolism               3       40         3.17*E* − 03   5162, 4191, 38
  *P*6+       Terpenoid backbone biosynthesis   2       15         3.20*E* − 02   2224, 38
  *P*7−       Pyrimidine metabolism             3       95         2.72*E* − 02   54963, 5435, 5430
  *P*7+       Methane metabolism                2       6          1.52*E* − 02   128, 4524
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